Binding studies of [3H]-spiroperidol, a potent dopamine antagonist, were performed on dispersed cells obtained from 2 mixed PRL- and GH-secreting adenomas, 3 GH-secreting adenomas and 4 'nonsecreting' pituitary tumors. Saturable, high affinity binding sites for [3H]-spiroperidol were identified in the two adenomas of mixed PRL and GH secretion, in 2 of 3 GH-secreting adenomas and in 2 of 4 'nonsecreting' adenomas. These data indicate that dopaminergic binding sites are present in some GH-secreting adenomas in the absence of PRL hypersecretion and in some 'nonsecreting' pituitary adenomas.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1159/000179873 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A single-center prospective study evaluating the relationship of tumor consistency on remission in acromegaly patients.
Sci Rep
January 2025
Department of Neurosurgery, Bahcesehir Universty School of Medicine, Istanbul, Turkey.
The nature of somatotroph adenomas has not been clearly revealed in studies. We consider that there are macroscopic differences in intraoperative tumor consistency in acromegaly patients. We aimed to determine whether there is a relationship between intraoperative tumor consistency and histopathological subtypes by planning a prospective study to determine whether these differences are significant.
View Article and Find Full Text PDFPolycystic Ovary Syndrome in the Context of Pituitary Adenomas: Prevalence, Pathophysiology and Clinical Management.
Clin Endocrinol (Oxf)
December 2024
Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy.
Objective: Many review articles have explored data regarding the coexistence of specific types of pituitary adenomas (PAs) and polycystic ovary syndrome (PCOS), particularly focusing on the potential pathogenesis of this intersection and overlapping features. However, a comprehensive evaluation encompassing the full spectrum of PAs and their association with PCOS remains lacking. This review aims to provide a broad assessment of the interactions between these entities, emphasizing pathophysiological mechanisms, clinical presentations, diagnostic challenges and therapeutic implications.
View Article and Find Full Text PDFDigital quantification of somatostatin receptor subtypes 2 and 5 in growth hormone-secreting pituitary tumors.
Eur J Endocrinol
January 2025
Endocrinology Unit, Department of Internal Medicine and Medical Specialties (DIMI), University of Genova, 16132 Genova, Italy.
Immunohistochemistry (IHC) of somatostatin receptor subtype 2 can predict response to first-generation somatostatin receptor ligands (fg-SRLs) in acromegaly. Recently, we validated an open-source digital image analysis (DIA) to quantify somatostatin receptor subtype 2 (SSTR2) expression. We aimed to validate the DIA also on somatostatin receptor subtype 5 (SSTR5) in a new cohort of growth hormone (GH)-secreting pituitary tumors, with IHC performed in a different laboratory, and to correlate fg-SRL response with SSTs expression.
View Article and Find Full Text PDFPituitary adenomas in children: surgical course and functional outcome. Lille cohort retrospective study.
Neurochirurgie
December 2024
Lille University Hospital, Neurosurgery Department, PRISM Lab Inserm U1192, CHU LilleF-59000, Lille France.
Context: Pituitary Neuroendocrine Tumors are rare in children, but challenging, implying the two purposes to cure the child, and preserve pituitary function. In this paper, we describe our population of children who underwent endoscopic endonasal resection of a pituitary adenoma, in Lille University Hospital.
Patients And Methods: Between 2007 and 2021, all children undergoing EEN surgery for pituitary adenoma were included.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!